JAK: Not Just Another Kinase.
Agashe RP, Lippman SM, Kurzrock R.
Agashe RP, et al.
Mol Cancer Ther. 2022 Dec 2;21(12):1757-1764. doi: 10.1158/1535-7163.MCT-22-0323.
Mol Cancer Ther. 2022.
PMID: 36252553
Free PMC article.
Review.
Somatic gain-of-function JAK mutations mainly occur in hematologic malignancies, with the activating JAK2 V617F being a myeloproliferative disorder hallmark; it is also seen in clonal hematopoiesis of indeterminate potential. Several T-cell malignancies, as well as …
Somatic gain-of-function JAK mutations mainly occur in hematologic malignancies, with the activating JAK2 V617F being a myeloproliferative d …